Abeona Therapeutics (NASDAQ: ABEO)
Key Data Points
Abeona Therapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Abeona Therapeutics Company Info
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
News & Analysis
Here's Why Abeona Therapeutics Fell as Much as 43.8% Today
The small-cap company announced the pricing of a public stock offering.
3 Small-Cap Biotech Stocks to Keep on Your Radar
Small market caps. Big opportunities.
Here's Why Abeona Therapeutics Stock Dropped 12% Today
A clinical trial update for AB-102 didn't go far enough.
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these red-hot biotech stocks keep the momentum going?
Why Abeona Therapeutics Jumped 14% on Wednesday
Positive clinical trial data from a single patient sends shares soaring.
Here's Why Abeona Therapeutics Inc. Stock Spiked Today
The red-hot gene therapy start-up took a big step towards its first potential new drug application.
Why Abeona Therapeutics Inc Stock Jumped Higher Today
An analyst started coverage at a buy, but there's more that long-term investors should be focused on.
3 Biotech Stocks That Skyrocketed This Week
Abeona, Sangamo, and Juno ride the huge wave resulting from Gilead Sciences' acquisition of Kite Pharma.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.